---
title: "Wave Life Sciences Q4 revenue beats analyst expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277043108.md"
datetime: "2026-02-26T12:47:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277043108.md)
  - [en](https://longbridge.com/en/news/277043108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277043108.md)
---

# Wave Life Sciences Q4 revenue beats analyst expectations

)

Overview

-   Biotechnology firm’s Q4 revenue beat analyst expectations
-   Net income and income from operations missed analyst estimates
-   Company advancing RNA medicines pipeline with multiple clinical trials in 2026

Outlook

-   Wave plans to initiate Phase 2a trial for WVE-007 in 1H 2026
-   Company expects regulatory feedback on WVE-006 approval pathway mid-2026
-   Wave aims to file CTA for WVE-008 for liver disease in 2026

Result Drivers

-   OBESITY TREATMENT - WVE-007 showed promising interim results in fat loss comparable to GLP-1, with muscle preservation, supporting its potential as a transformative obesity treatment
-   AATD ADVANCEMENTS - WVE-006 achieved key treatment goals for AATD, with dynamic AAT production and favorable safety, advancing towards potential accelerated approval
-   LIVER DISEASE FOCUS - WVE-008 is advancing for PNPLA3 I148M liver disease, with preparations for a clinical trial application in 2026 Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $17.24 $16.30

Revenue mln mln (16

Analysts

)

### Q4 EPS -$0.30

Q4 Net Miss -$53.18 -$45.92

Income mln mln (15

Analysts

)

Q4 Miss -$56.47 -$48.53

Income mln mln (15

from Analysts

Operatio )

ns

Q4 Miss -$53.18 -$45.67

Pretax mln mln (14

Profit Analysts

)

### Q4 $73.71

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 16 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for WAVE Life Sciences Ltd is $32.50, about 123.5% above its February 25 closing price of $14.54 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [WVE.US](https://longbridge.com/en/quote/WVE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBC.US](https://longbridge.com/en/quote/BBC.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Wave Life Sciences (WVE) Is Up 14.4% After Phase 1 Data On Long‑Acting Obesity Drug WVE‑007](https://longbridge.com/en/news/281712132.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery](https://longbridge.com/en/news/282641629.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance](https://longbridge.com/en/news/282227475.md)